Pentoxifylline - a review of its use in osteoradionecrosis.

A J Lyons, P A Brennan

Journal: The British journal of oral & maxillofacial surgery 2018;55(3):230-234

PMID: 28034471

Full Text on Elsevier Science View on PubMed

Abstract

Pentoxifylline has been used to treat complications related to fibrosis for over 20 years. Formerly used to treat those after radiotherapy such as osteoradionecrosis (ORN), it is now being tried for medication-related osteonecrosis of the jaw (MRONJ), which can occur after prolonged use of bisphosphonates. We review theories on the formation of fibrosis in patients with ORN, discuss the pharmacology of pentoxifylline and vitamin E, and report published outcomes. To our knowledge no prospective randomised controlled trial has investigated the benefits of these agents in cases of ORN, but reported outcomes in many published case series are encouraging.

Address: Head and Neck Unit, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT. Electronic address: [email protected].; Maxillofacial Unit, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK. Electronic address: [email protected].

DOI: 10.1016/j.bjoms.2016.12.006

Link outs

Free resources

Medical:

https://medlineplus.gov/jawinjuriesanddisorders.ht...

Other Literature Sources:

https://scite.ai/reports/28034471

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Jaw Diseases, Osteoradionecrosis, Pentoxifylline